Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Bankole A. Johnson |
Documentos disponibles escritos por este autor (2)
Refinar búsquedaDose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects / Bankole A. Johnson en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 3 (Junio)
Título : Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects Tipo de documento: texto impreso Autores: Bankole A. Johnson, Autor ; Stephanie S. O’Malley, Autor Fecha de publicación: 2023 Artículo en la página: pp. 281-293 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Alcoholismo, Terapia con medicamentos, Naltrexona, Pruebas neuropsicológicas, Taurina. Resumen: We examined kinetic and dynamic factors to determine the pharmacological and behavioral safety and tolerability of low versus high doses of an opiate antagonist, naltrexone (50 mg/day vs. 100 mg/day), and acamprosate (2 g/day vs. 3 g/day), a functional N-methyl-D-aspartate receptor antagonist, both independently and combined, among non-treatmentseeking, alcohol-dependent individuals. Link: ./index.php?lvl=notice_display&id=31024
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 281-293[artículo] Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects [texto impreso] / Bankole A. Johnson, Autor ; Stephanie S. O’Malley, Autor . - 2023 . - pp. 281-293.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 281-293
Palabras clave: Alcoholismo, Terapia con medicamentos, Naltrexona, Pruebas neuropsicológicas, Taurina. Resumen: We examined kinetic and dynamic factors to determine the pharmacological and behavioral safety and tolerability of low versus high doses of an opiate antagonist, naltrexone (50 mg/day vs. 100 mg/day), and acamprosate (2 g/day vs. 3 g/day), a functional N-methyl-D-aspartate receptor antagonist, both independently and combined, among non-treatmentseeking, alcohol-dependent individuals. Link: ./index.php?lvl=notice_display&id=31024
Título : Effects of isradipine on cocaine induced subjective mood Tipo de documento: texto impreso Autores: Bankole A. Johnson, Autor ; John D. Roache, Autor ; Nassima Ait Daoud, Autor Fecha de publicación: 2023 Artículo en la página: pp. 180-191 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Afecto, Bloqueadores de los canales de calcio, Bloqueadores de los canales de calcio, Cocaína - farmacología, Trastornos relacionados con la cocaína, Dopamina, Isradipina. Resumen: We hypothesized that in humans, as in animals, isradipine, a dihydropyridine-class calcium channel antagonist, would antagonize cocaine's rewarding effects, based on preclinical evidence that isradipine inhibits cocaine-mediated increases in mesolimbic dopamine (DA), thereby reducing cocaine's abuse liability. Confirmation of our hypothesis would make isradipine a promising medication for treating cocaine dependence. Link: ./index.php?lvl=notice_display&id=30968
in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 2 (Abril) . - pp. 180-191[artículo] Effects of isradipine on cocaine induced subjective mood [texto impreso] / Bankole A. Johnson, Autor ; John D. Roache, Autor ; Nassima Ait Daoud, Autor . - 2023 . - pp. 180-191.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 2 (Abril) . - pp. 180-191
Palabras clave: Afecto, Bloqueadores de los canales de calcio, Bloqueadores de los canales de calcio, Cocaína - farmacología, Trastornos relacionados con la cocaína, Dopamina, Isradipina. Resumen: We hypothesized that in humans, as in animals, isradipine, a dihydropyridine-class calcium channel antagonist, would antagonize cocaine's rewarding effects, based on preclinical evidence that isradipine inhibits cocaine-mediated increases in mesolimbic dopamine (DA), thereby reducing cocaine's abuse liability. Confirmation of our hypothesis would make isradipine a promising medication for treating cocaine dependence. Link: ./index.php?lvl=notice_display&id=30968
